Quick Answer
Cytek Biosciences, Inc. reported Stockholders Equity of $341.74 million for the year ending 2025.
- Cytek Biosciences, Inc. showed a decrease of -13.6% in Stockholders Equity from 2024 to 2025.
- This data is from Cytek Biosciences, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: -$42.50 million | Q2 2020: -$34.30 million | Q3 2020: -$27.39 million | Q1 2021: -$14.76 million | Q2 2021: -$10.99 million | Q3 2021: $403.20 million | Q1 2022: $407.44 million | Q2 2022: $411.13 million | Q3 2022: $416.51 million | Q1 2023: $423.46 million | Q2 2023: $424.18 million | Q3 2023: $415.52 million | Q4 2023: $393.06 million | Q1 2024: $392.61 million | Q2 2024: $389.12 million | Q3 2024: $385.46 million | Q1 2025: $379.62 million | Q2 2025: $377.56 million | Q3 2025: $378.57 million.
- Over the full 7 years of available data (2019 to 2025), Cytek Biosciences, Inc.'s Stockholders Equity has grown by 719.5%.
- Historical annual values: Fiscal year 2025: $341.74 million | Fiscal year 2024: $395.74 million | Fiscal year 2023: $393.06 million | Fiscal year 2022: $425.55 million | Fiscal year 2021: $405.39 million | Fiscal year 2020: -$16.03 million | Fiscal year 2019: $41.70 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: